Cargando…
Pharmacodynamic Effects of Topical Omiganan in Patients With Mild to Moderate Atopic Dermatitis in a Randomized, Placebo‐Controlled, Phase II Trial
Omiganan is an indolicidin analog with antimicrobial properties that could be beneficial for patients with atopic dermatitis. In this randomized, double‐blind, placebo‐controlled, phase II trial we explored the efficacy, pharmacodynamics, and safety of topical omiganan once daily in 36 patients with...
Autores principales: | Niemeyer‐van der Kolk, Tessa, van der Wall, Hein, Hogendoorn, Geretta K., Rijneveld, Rianne, Luijten, Sascha, van Alewijk, Dirk C.J.G., van den Munckhof, Ellen H.A., de Kam, Marieke L., Feiss, Gary L., Prens, Errol P., Burggraaf, Jacobus, Rissmann, Robert, van Doorn, Martijn B.A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7485951/ https://www.ncbi.nlm.nih.gov/pubmed/32315497 http://dx.doi.org/10.1111/cts.12792 |
Ejemplares similares
-
Omiganan Enhances Imiquimod‐Induced Inflammatory Responses in Skin of Healthy Volunteers
por: Niemeyer‐van der Kolk, Tessa, et al.
Publicado: (2020) -
Comprehensive, Multimodal Characterization of an Imiquimod‐Induced Human Skin Inflammation Model for Drug Development
por: van der Kolk, Tessa, et al.
Publicado: (2018) -
Treatment with the Topical Antimicrobial Peptide Omiganan in Mild-to-Moderate Facial Seborrheic Dermatitis versus Ketoconazole and Placebo: Results of a Randomized Controlled Proof-of-Concept Trial
por: Rousel, Jannik, et al.
Publicado: (2023) -
Inter- and Intra-patient Variability Over Time of Lesional Skin Microbiota in Adult Patients with Atopic Dermatitis
por: VAN DEN MUNCKHOF, Ellen H. A., et al.
Publicado: (2020) -
Stereophotogrammetric three‐dimensional photography is an accurate and precise planimetric method for the clinical visualization and quantification of human papilloma virus‐induced skin lesions
por: Rijsbergen, M., et al.
Publicado: (2019)